Curiosity may have killed the cat, but that didn't keep a team of Wall Street Journal reporters from getting unnamed sources to spill the beans about Pfizer's
According to the Journal, Pfizer is leaning toward spinning off its animal health division, rather than selling the unit to the highest bidder. A sale would have tax implications for Pfizer, but the real problem here is likely the company's inability to sell the unit as one big package. A lot of animal-health products that only have two or the three competitors. If any of Pfizer's competitors wanted to buy the unit, antitrust regulators would likely make them shed products of their own.
Giving investors shares of a spinoff would likely be a tax-free event and solve the antitrust issue, but it doesn't allow Pfizer to gain any cash. The company has about $24 billion in cash and short-term investments, but large pharmas can never have too much cash to go hog-wild with licensing deals. And let's not forget that Pfizer has $35 billion in long-term debt.
One solution would be to follow the path Bristol-Myers Squibb
The unnamed sources are often right. But until you hear it from the horse's mouth, it's probably best not to make any investment decisions based on rumors.
Keep track of all our Foolish analysis on Pfizer as it gets smaller by adding it to the Fool's free My Watchlist service. Just click here to get started.
Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.